{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:38:29Z","timestamp":1792028309635,"version":"4.4.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Percutaneous renal biopsy (PRB) provides valuable information to guide treatment decisions in patients with metastatic renal cell carcinoma (mRCC) who develop acute kidney injury (AKI) after systemic anticancer therapy (SACT). The rising incidence of renal cell carcinoma (RCC) and the substantial impact of SACT on overall survival suggest a higher prevalence of RCC patients with reduced nephron mass and a solitary kidney (SK) requiring PRB for AKI. However, safety data on SK biopsies are scarce, and the potential for dialysis-requiring complications may deter clinicians.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective case series reports the safety of 13 PRBs in 12 mRCC patients with reduced nephron mass who developed AKI during SACT as well as six PRBs in six patients with metastatic solid malignancies and AKI, which developed during SACT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven biopsies in mRCC patients and five biopsies in patients with metastatic solid malignancies were uneventful. One patient with mRCC experienced a major bleeding event due to an arteriovenous (AV) fistula seven days post-procedure, while another mRCC patient developed macrohematuria within 24 hours. In the group of patients with metastatic solid malignancies, one patient experienced a small perinephric hematoma during the observational period. Despite the small sample size, individual chart reviews and direct management of adverse events allowed assessment of the association between biopsy and complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Until further data become available, a longer observation period is recommended for these patient cohorts compared to the general population. Further studies are needed to develop consensus guidelines for PRB in mRCC patients with reduced nephron mass.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneph.2025.1615779","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:07Z","timestamp":1754453527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The safety of percutaneous renal biopsy for acute kidney injury in metastatic renal cell cancer patients with reduced nephron mass"],"prefix":"10.3389","volume":"5","author":[{"given":"Tomaz","family":"Milanez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Premru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miha","family":"Arnol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Ocvirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.34067\/kid.0001072019","article-title":"Kidney biopsy should be performed to document the cause of immune checkpoint inhibitor\u2013associated acute kidney injury: Commentary","volume":"1","author":"Perazella","year":"2020","journal-title":"Kidney360"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.964335","article-title":"The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Moss","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2021.10.004","article-title":"Outcomes of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: real world data from Canadian centers","volume":"8","author":"Dragomir","year":"2022","journal-title":"Eur Urol Focus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00380-1","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.12.026","article-title":"Biopsying diabetics \u2026 How risky is it","volume":"7","author":"Taliercio","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.ajkd.2012.02.330","article-title":"Bleeding complications of native kidney biopsy: a systematic review and meta-analysis","volume":"60","author":"Corapi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000504544","article-title":"Risk factors associated with major complications after ultrasound-guided percutaneous renal biopsy of native kidneys","volume":"45","author":"Pombas","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac177","article-title":"The risks associated with percutaneous native kidney biopsies: a prospective study","volume":"38","author":"Andrulli","year":"2023","journal-title":"Nephrol Dial Transpl"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002432021","article-title":"Bleeding complications of percutaneous kidney biopsy: Does gender matter","volume":"2","author":"Anpalahan","year":"2021","journal-title":"Kidney360"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05750515","article-title":"The native kidney biopsy: update and evidence for best practice","volume":"11","author":"Hogan","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx012","article-title":"Risk factors for bleeding complications after nephrologist-performed native renal biopsy","volume":"10","author":"Lees","year":"2017","journal-title":"Clin Kidney J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12882-021-02505-9","article-title":"Kidney biopsy practice amongst Australasian nephrologists","volume":"22","author":"Burke","year":"2021","journal-title":"BMC Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90592-8","article-title":"Outcomes of percutaneous kidney biopsy, including those of solitary native kidneys","volume":"26","author":"Mendelssohn","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx102","article-title":"Trends and outcomes of the use of percutaneous native kidney biopsy in the United States: 5-year data analysis of the Nationwide Inpatient Sample","volume":"11","author":"Al Turk","year":"2018","journal-title":"Clin Kidney J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12882-017-0786-0","article-title":"Arteriovenous fistulae after renal biopsy: diagnosis and outcomes using Doppler ultrasound assessment","volume":"18","author":"Sosa-Barrios","year":"2017","journal-title":"BMC Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196424","article-title":"Renal biopsy for diagnosis in kidney disease: indication, technique, and safety","volume":"12","author":"Schnuelle","year":"2023","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without Malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J Thromb Haemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000091","article-title":"Effects of aspirin on kidney biopsy bleeding complications: a systematic review and meta-analysis (PROSPERO 2021 CRD42021261005)","volume":"4","author":"Relvas","year":"2023","journal-title":"Kidney360"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13879","article-title":"Safety and utility of kidney biopsy in patients with estimated glomerular filtration rate\u2009<\u200930 ml\/min\/1.73\u2009m2","volume":"26","author":"Asad","year":"2021","journal-title":"Nephrol (Carlton)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz132","article-title":"Clinical parameters predicting complications in native kidney biopsies","volume":"13","author":"Peters","year":"2019","journal-title":"Clin Kidney J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.18391120","article-title":"Systematic review and meta-analysis of native kidney biopsy complications","volume":"15","author":"Poggio","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04910418","article-title":"Kidney biopsy-related complications in hospitalized patients with acute kidney disease","volume":"13","author":"Moledina","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/01.asn.0000102472.37947.14","article-title":"Timing of complications in percutaneous renal biopsy","volume":"15","author":"Whittier","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s0272-6386(96)90129-8","article-title":"Timing of complications in percutaneous renal biopsy: what is the optimal period of observation","volume":"28","author":"Marwah","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz157","article-title":"How long should patients be observed after percutaneous kidney biopsies","volume":"34","author":"Abuelo","year":"2019","journal-title":"Nephrol Dial Transpl"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1615779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:08Z","timestamp":1754453528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1615779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":33,"alternative-id":["10.3389\/fneph.2025.1615779"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1615779","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1615779"}}